Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer
Current treatment for non-small cell lung cancer (NSCLC) remains inadequate. Vorinostat is
a novel agent that inhibits the enzymatic activity of histone deacetylases (HDACs).
Bortezomib is a small molecule proteasome inhibitor. Preclinical and clinical studies have
shown the advantages of combining these two agents in the treatment of NSCLC
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Three-month progression-free survival
Tien Hoang, M.D.
University of Wisconsin, Madison
United States: Institutional Review Board